AEZS - Aeterna Zentaris Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Aeterna Zentaris Inc.

315 Sigma Drive
Suite 302D
Summerville, SC 29486
United States
843-900-3223
http://www.aezsinc.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael V. WardPres & CEON/AN/A1957
Mr. James ClavijoCFO & Sec.N/AN/A1966
Mr. Paul BurroughsDirector of CommunicationsN/AN/AN/A
Dr. Nicola AmmerChief Medical Officer & VP of Clinical Devel.N/AN/AN/A
Mr. Brian GarrisonSr. VP of Global Commercial OperationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Corporate Governance

Aeterna Zentaris Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.